Fineline Cube

Follow:
14778 Articles
Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
CompanyDeals

Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round

Aosaikang's Generic Livtencity Accepted for Review by China's NMPA
CompanyDrug

Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA

Sinobioway Biomedicine Partners with Happy Life Tech for Clinical Trial Services
CompanyDeals

Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services

Balance Medtech's Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA
CompanyMedical Device

Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA

MicuRx Pharmaceuticals' MRX-5 Receives NMPA Approval for NTM Infections Clinical Study
CompanyDrug

MicuRx Pharmaceuticals’ MRX-5 Receives NMPA Approval for NTM Infections Clinical Study

Huahai Pharmaceutical's HB0028 and HB002.1T Cleared for Clinical Study by NMPA
CompanyDrug

Huahai Pharmaceutical’s HB0028 and HB002.1T Cleared for Clinical Study by NMPA

Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial

China's State Council Aims to Enhance Drug and Medical Device Regulation by 2027
Policy / Regulatory

China’s State Council Aims to Enhance Drug and Medical Device Regulation by 2027

Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding
Company

Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding

AstraZeneca's Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment
CompanyDrug

AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment

NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients
CompanyDrug

NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients

Gilead Sciences' Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection
CompanyDrug

Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection